Low-dose oral sirolimus appears to increase the risk of menstrual-cycle disturbances and ovarian cysts. Monitoring patients for sirolimus-associated ovarian toxicity may be considered.
No takes yet. Share an insight, caveat, or question.
Braun et al. (2012) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: